about
In vivo dynamical interactions between CD4 Tregs, CD8 Tregs and CD4+ CD25- cells in miceThe tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy.A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy.Empowering Regulatory T Cells in Autoimmunity.Editorial: Molecules Balancing Immunological Surveillance against Cancer and Autoimmune Diseases.Bcl-xL affects the development of functional CD4 Tregs.B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study.Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.The serine/threonine protein phosphatase 2A controls autoimmunity.Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System.Induced Sputum Analysis in Subjects With Systemic Sclerosis.Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse modelBcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptideRegulatory T cells in the treatment of diseasePrecision DNA demethylation ameliorates disease in lupus-prone micePP2A enables IL-2 signaling by preserving IL-2Rβ chain expression during Treg development.Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestationsAmelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNKThe suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cellsAmelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosisInduction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestationsThe role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine modelsA tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 miceA new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptideA role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide
P50
Q33521228-7EBF1DEA-7EF6-4688-8B96-2470FF71A6EFQ34653846-00BB9DC6-DB19-4905-821F-7F4B76886ACCQ34697271-B743F005-144D-4D39-ABCC-36DD1C212645Q37732959-2FD1D756-FA38-401D-A0D9-905DA52A894FQ37775735-CEE8DF53-5277-4C48-A2A8-818B7CC61836Q38222711-2CA312F5-9DBB-42BB-9F77-6AF311AAD328Q38729516-19F7FA5D-BE7E-41D4-90E2-8D9F64AAA685Q38909420-6F145321-7659-4857-ACC9-25A2D7D608E9Q40078956-2BAE63A5-3507-494C-AECE-D46D76879356Q42420372-8570A1CB-5270-419B-853F-C25CD087A938Q46136079-19027846-982D-4D9D-8007-8543D03542E6Q47734804-F9BFB048-7F43-4467-945F-F1C7F30EE8B7Q48393817-09DC5BFB-7E39-4982-90E6-97CDF025271FQ50875190-C82D221F-23ED-43AE-B70C-CAA5517BE099Q51020649-F97366D2-F4FA-4E52-B66C-D7AC30F30786Q51511201-A4E4B034-18E3-436F-813D-8071B8FE884DQ51735214-85AB1E7D-F2F5-45FD-BC0D-F79D06CA2AAAQ51772317-911B5FE0-0EC9-46A4-9FA0-6CA686DA869EQ54465969-C4635E31-770F-4BBF-A81E-C9A054A0D2D1Q56899357-0F5EA65B-4675-42DA-9B11-EA81EB58D130Q56899682-608AB9F9-0C2D-4A02-AF02-B1C9891DD66AQ57471979-AE2D4F5D-21EC-4DE6-B9A1-B3240C3CCB8EQ58710822-D364909B-8B24-4441-A32E-02DD485D1697Q64945620-C50E3BA0-8284-4CAC-8FA0-2E5C47BDD028Q80544801-3F2D25D6-470D-4AEC-8B85-6CF2A11B818BQ81417589-465616B1-F02A-48D1-A60D-829EF94C1DA6Q81803384-C9898008-1631-4C3D-9139-0558233C7F85Q82669390-3328BC9E-8CA0-422C-8F99-2EF386BF3D1CQ82729433-30CC7CEB-F657-4B91-8FAF-2AE820DF5557Q82758762-74691EA5-62C2-4643-BA74-6F6EABBDF127Q84290859-C1D3D115-9EF8-4E98-96CF-A2FB528517A9Q84564479-707CF07E-8CE7-4275-B6FA-A89C7CCF03E8Q84803684-9EA71159-4C5C-4690-9379-A0CD4F11AA4D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amir Sharabi
@ast
Amir Sharabi
@en
Amir Sharabi
@es
Amir Sharabi
@nl
type
label
Amir Sharabi
@ast
Amir Sharabi
@en
Amir Sharabi
@es
Amir Sharabi
@nl
prefLabel
Amir Sharabi
@ast
Amir Sharabi
@en
Amir Sharabi
@es
Amir Sharabi
@nl
P106
P21
P31
P496
0000-0002-6242-6774